Polyene antifungal for topical/oral use indicated for non-esophageal gastrointestinal mucosal candidiasis (oral forms) and cutaneous and mucocutaneous candidiasis (topical forms).
Also known as: Nystan, Micostatin, nystatin
DailyMed approved label (Nystatin Tablet; setID 197e3046-3e58-4246-b260-f3995dce41a1).
DailyMed approved label (Nystatin Tablet; setID 197e3046-3e58-4246-b260-f3995dce41a1).
No documented drug–drug interactions for this medicine.
Oral nystatin suspension should be kept in contact with the oral mucosa; food may interfere with adherence.
Give after meals and keep in contact with the lesions.
EMC-UK (MHRA) — approved Nystatin SmPC: https://www.medicines.org.uk/emc/product/408/smpc
Nystatin is generally well tolerated; hypersensitivity reactions are rare but possible in sensitised patients.
Stop at a hypersensitivity reaction.
DailyMed approved label (Nystatin Tablet; setID 197e3046-3e58-4246-b260-f3995dce41a1).
Oral nystatin acts locally on the mucosa; severe gastrointestinal disease can reduce the efficacy of local contact.
Consider adapted formulations and ensure prolonged contact with the mucosa.
DailyMed approved label (Nystatin Tablet; setID 197e3046-3e58-4246-b260-f3995dce41a1).
Oral nystatin has minimal systemic absorption and is the antifungal of choice for oral candidiasis in pregnancy.
Can be used in all trimesters.
Excretion into breast milk is negligible; compatible with breastfeeding.
No specific additional contraception.
EMC-UK (MHRA) — approved Nystatin SmPC: https://www.medicines.org.uk/emc/product/408/smpc
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Polyene antifungal with fungistatic and fungicidal effect against yeasts and yeast-like fungi: binds to sterols in the cell membrane of susceptible Candida species, altering permeability and allowing leakage of intracellular components.
Binding to fungal membrane sterols (ergosterol), altering permeability and causing cell lysis; no appreciable activity against bacteria, protozoa or viruses.
Insignificant GI absorption: most of the oral dose is eliminated unchanged in feces; significant plasma concentrations may occur in patients with renal insufficiency.
Minimal hepatic metabolism (acts locally in the GI lumen).
Not applicable orally (no significant systemic absorption).
Medicines from the same therapeutic group (ATC classification) or the same pharmacological class.
